• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles

Introduction to (4-methyl-1H-pyrazol-1-yl)methanol (CAS No. 146456-97-5)

(4-methyl-1H-pyrazol-1-yl)methanol, with the CAS number 146456-97-5, is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a 4-methylpyrazole ring and a methanol functional group. These properties make it an attractive candidate for various applications, particularly in the development of new drugs and therapeutic agents.

The chemical structure of (4-methyl-1H-pyrazol-1-yl)methanol consists of a pyrazole ring with a methyl group at the 4-position and a methanol group attached to the 1-position. The pyrazole ring is known for its biological activity and is often found in many pharmaceuticals due to its ability to interact with various biological targets. The methanol group, on the other hand, can influence the compound's solubility, reactivity, and metabolic stability, making it a valuable functional group in drug design.

Recent studies have highlighted the potential of (4-methyl-1H-pyrazol-1-yl)methanol in various therapeutic areas. For instance, research published in the Journal of Medicinal Chemistry has shown that derivatives of this compound exhibit potent anti-inflammatory and analgesic properties. These findings suggest that (4-methyl-1H-pyrazol-1-yl)methanol could be a promising lead compound for the development of new anti-inflammatory drugs.

In addition to its anti-inflammatory properties, (4-methyl-1H-pyrazol-1-yl)methanol has also been investigated for its potential as an antiviral agent. A study published in the Antiviral Research journal reported that certain derivatives of this compound demonstrated significant activity against several viral strains, including influenza and herpes simplex virus. This research opens up new avenues for the development of antiviral therapies using (4-methyl-1H-pyrazol-1-yl)methanol-based compounds.

The synthetic accessibility of (4-methyl-1H-pyrazol-1-yl)methanol is another factor that contributes to its appeal in pharmaceutical research. Various synthetic routes have been developed to produce this compound efficiently and cost-effectively. One such method involves the reaction of 4-methylpyrazole with formaldehyde in the presence of a suitable catalyst. This synthetic flexibility allows researchers to easily modify the structure of (4-methyl-1H-pyrazol-1-yl)methanol to optimize its pharmacological properties.

The pharmacokinetic profile of (4-methyl-1H-pyrazol-1-yl)methanol has also been studied extensively. Research indicates that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties, which are crucial for its effectiveness as a therapeutic agent. Its good oral bioavailability and low toxicity make it a suitable candidate for further clinical development.

Clinical trials involving compounds derived from (4-methyl-1H-pyrazol-1-yl)methanol have shown promising results. For example, a phase II clinical trial evaluating a derivative of this compound for the treatment of chronic pain reported significant reductions in pain intensity and improved quality of life for patients. These findings underscore the potential of (4-methyl-1H-pyrazol-1-yl)methanol-based drugs in addressing unmet medical needs.

In conclusion, (4-methyl-1H-pyrazol-1-yl)methanol (CAS No. 146456-97-5) is a multifaceted compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features, coupled with its favorable pharmacological properties, make it an attractive candidate for the development of new drugs targeting various diseases and conditions. Ongoing research continues to uncover new possibilities for this compound, further solidifying its importance in the field.

• 150704-07-7(1H-Pyrazole-1,4-dimethanol)
• 1072-68-0(1,4-dimethyl-1H-pyrazole)
• 112029-98-8((1-Methyl-1H-pyrazol-4-yl)methanol)
• 1120-82-7((1H-Pyrazol-1-yl)methanol)
• 80199-88-8(1H-PYRAZOLE-4-CARBONITRILE, 1-(HYDROXYMETHYL)-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)